ForPatients
by Roche

Cancer

A Study to Assess Pharmacokinetics and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy to Chinese Participants With Locally Advanced or Metastatic Solid Tumors

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Countries	NCT02825940 YO29233

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This Phase I, open-label, multicenter study will evaluate the pharmacokinetics, safety, and preliminary anti-tumor activity of atezolizumab as monotherapy in Chinese participants with locally advanced or metastatic gastric cancer, nasopharyngeal cancer, esophageal cancer, and hepatocellular carcinoma (HCC) that are refractory to standard therapeutic modalities and for whom no further standard therapy is available or who have refused standard therapy; and the safety and preliminary anti-tumor activity of atezolizumab in combination with gemcitabine and cisplatin in Chinese participants with Stage IV, treatment-naive non-small cell lung cancer (NSCLC). The study will consist of a pharmacokinetic (PK) phase and an extension phase.

Hoffmann-La Roche	Phase 1
Sponsor	Phase

NCT02825940 YO29233
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>= 18 Years	No